Skip to main content
. 2020 Jun 12;12(6):1563. doi: 10.3390/cancers12061563

Figure 5.

Figure 5

Immunogenicity and immunoprotection of female mice inoculated with Fhit-transfected B9/B11 tumor cells. (A) TB9- and TB11-Fhit immunoprotected the hosts against B9 and B11 tumor cells. The animals (n = 10 mice per group) were previously inoculated with Fhit-transfected tumor cells and then, 60 days later, inoculated with non-transfected tumor cells; B9 and B11 tumor cells were immune rejected in all mice; (B) TB9- and TB11-Fhit immunoprotected the hosts against other tumor cell clones of the GR9 tumor system and even against GR9 bulk tumor cells; (C) TB9- and TB11-Fhit did not immunoprotect the hosts against 4T1 breast carcinoma cells or CT26 colon carcinoma cells. The assays were repeated twice.